EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneity

Amro Maarouf, Manjit K Shergill, Alan F Jones, John Marriott, Sudarshan Ramachandran

Journal of Cardiovascular Diseases · 13.11.2025 · 14 (1)

DOI: 10.52338/jocd.2025.5198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Diseases, online erschienen am 13.11.2025. Verfasst von Amro Maarouf und 4 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We describe decreases in total cholesterol (TC), non-high density lipoprotein-cholesterol (non-HDL-C) and low density lipoprotein- cholesterol (LDL-C) following bempedoic acid treatment in an out-patient setting and compare the results to those observed in phase 3 efficacy trials.

Design

We analysed a cohort of 113 patients not achieving LDL-C targets commenced on bempedoic acid after previous treatment with statins and ezetimibe using an intention-to-treat approach.

Methods

We compared pre and post bempedoic acid treatment lipids (3-months) in the total cohort using paired t-tests. Baseline patient characteristics associated with LDL-C decrease was established via linear/multiple regression analyses.

Results

Following bempedoic acid treatment absolute reduction (mean ± SD) in TC, non-HDL-C, and LDL-C values were 1.1 ± 1.0mmol/L, 1.0 ± 1.0mmol/L, and 1.0 ± 0.9mmol/L, respectively, whilst percentage reductions (mean ± SD) were 16.4 ± 14.1%, 18.8 ± 17.2%, and 23.2 ± 20.5%, respectively. Significant decreases in lipids were observed in every subgroup studied. The LDL-C decrease following bempedoic acid was independently greater in ex-smokers, individuals on ezetimibe at baseline, and those with higher baseline LDL-C values.

Conclusions

Our results show that the LDL-C decrease seen with bempedoic acid was comparable to that observed in the phase 3 (CLEAR) efficacy trials. However, efficacy heterogeneity was observed in some of the subgroups studied such as patients on ezetimibe monotherapy or with higher LDL-C at baseline, the latter in accordance with the Wilder principle. The use of effect scores for identified patient subgroups might predict treatment response, enabling optimisation of lipid lowering efficacy.

Zitieren

APA

Maarouf, A., Shergill, M. K., Jones, A. F., Marriott, J., & Ramachandran, S. (2025). Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneity. Journal of Cardiovascular Diseases, 14(1). https://doi.org/10.52338/jocd.2025.5198

Vancouver

Maarouf A, Shergill MK, Jones AF, Marriott J, Ramachandran S. Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneity. Journal of Cardiovascular Diseases. 2025;14(1). doi:10.52338/jocd.2025.5198

BibTeX
@article{Maarouf2025,
  author = {Maarouf, Amro and Shergill, Manjit K and Jones, Alan F and Marriott, John and Ramachandran, Sudarshan},
  title = {Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneity},
  journal = {Journal of Cardiovascular Diseases},
  year = {2025},
  volume = {14},
  number = {1},
  doi = {10.52338/jocd.2025.5198}
}
Kostenlos starten →